Skip to content
PubMed This is a summary of 1 peer-reviewed journal articles Updated
Clinical Immunology

The Biology and Genetics of ICOSLG Deficiency

At a Glance

ICOSLG deficiency is a rare inherited immune disorder caused by harmful changes in both copies of the ICOSLG gene. The altered ICOSL protein stays inside cells instead of reaching their surface, weakening immune-cell communication, antibody memory, and the body's ability to fight infections.

The biology of ICOSLG deficiency is centered on a breakdown in communication between the different “branches” of your immune system. While your body has the raw materials to fight germs, it lacks the biological “bridge” required to coordinate a sophisticated, long-term defense.

The Genetic Blueprint: p.N219K

The most thoroughly documented genetic cause of this condition is a specific pathogenic variant (mutation) known as c.657C>G, which leads to a protein change called p.N219K [1].

  • Autosomal Recessive Inheritance: This condition follows a recessive pattern. For a person to be affected, they must inherit two pathogenic variants of the ICOSLG gene—one from each parent [1]. Parents are typically “carriers” who have one working copy and one non-working copy; they usually do not show any symptoms of the disease.
  • A “Rare among Rares”: This specific pathogenic variant is extremely rare. Because of its rarity, carrier risk cannot be accurately inferred from generalized genetic databases, and expert variant interpretation is necessary [1].

The Cellular “Traffic Jam”

In a healthy person, the ICOSL protein is manufactured inside the cell and then transported to the cell surface, where it acts like a signal or “key.” In ICOSLG deficiency, this manufacturing process goes wrong:

  1. Production: Your cells produce the ICOSL protein, but the pathogenic variant changes its physical shape [1].
  2. Retention: Because the protein is misshapen, it fails to reach the cell’s outer surface. Instead, it gets “stuck” inside the cell, primarily in structures called the endoplasmic reticulum and the Golgi apparatus [1].
  3. Silence: Because the “key” (ICOSL) is stuck inside the cell, it cannot reach the “lock” (ICOS) on the surface of your T cells. The crucial signal that should pass between these cells is impaired [1].

Downstream Effects on Your Defense

The loss of this signal has three major consequences for how your immune system functions:

1. Impaired Immune “Memory”

Normally, when your B cells meet a new germ, they talk to T cells to learn how to make high-quality antibodies. This process happens in a specialized area called a germinal center [1]. Without ICOSL, this conversation fails. As a result, the body’s ability to create certain memory B-cell responses is impaired, leading to a near-absence of switched-memory B cells—the specialized cells that remember a virus [1].

2. Impaired “Help” Signals

Without the ICOSL-ICOS bridge, your T cells do not produce enough of the chemical messengers (like IL-21) needed to support B-cell maturation. This leads to low levels of protective antibodies (hypogammaglobulinemia), making you more susceptible to bacteria like those that cause sinus and lung infections [1].

3. Barriers to Cell Movement

Unlike many other immune deficiencies, ICOSLG affects more than just blood cells. The ICOSL protein is also found on the lining of your blood vessels (endothelial cells) [1].

  • The Exit Problem: Normally, ICOSL helps white blood cells (like neutrophils and T cells) “stick” to and then crawl through the blood vessel wall to reach an infection in your tissues [1].
  • Trafficking Defect: In this condition, the lack of surface ICOSL makes it harder for neutrophils to exit the bloodstream. Separately, patients also experience neutropenia (low neutrophil counts in the blood). The exact relationship between the cell-migration defect and the low blood count is still an unresolved biological question [1].

ICOSLG vs. ICOS Deficiency

While they sound similar, these are two different biological problems. ICOS deficiency means the “lock” on the T cells is missing, whereas ICOSLG deficiency means the “key” on the B cells and blood vessel walls is missing [1]. Because ICOSL is found in more places throughout the body (including blood vessels), the symptoms and biological impacts may differ from those seen in ICOS deficiency [1].

A Note on Stem Cell Transplant (HSCT)

In some severe immune deficiencies, a hematopoietic stem cell transplant (HSCT) is used to “reset” the immune system. However, for ICOSLG deficiency, published outcomes are extremely limited, and HSCT remains an unresolved biological concern [1]. Because ICOSL is also found on the lining of blood vessels, a bone marrow transplant (which replaces blood cells) might not correct the blood vessel lining. Transplant decisions require extensive consultation with an expert transplant immunology team [1].

Common questions in this guide

What causes ICOSLG deficiency?
ICOSLG deficiency occurs when a person inherits two disease-causing variants in the ICOSLG gene, one from each parent. The best-documented variant is c.657C>G, which changes the protein at position 219, known as p.N219K. Parents with one altered copy are usually healthy carriers.
How does the p.N219K variant affect the immune system?
The p.N219K change alters the shape of ICOSL, so the protein can remain inside cells instead of reaching the cell surface. Without surface ICOSL, it cannot properly connect with ICOS on T cells, weakening signals needed for B-cell maturation, antibody production, and immune memory.
Why are switched-memory B cells and antibodies low in ICOSLG deficiency?
B cells normally receive help from T cells in germinal centers to mature and make high-quality, lasting antibodies. Impaired ICOSL-ICOS signaling reduces this help, which can lead to very low switched-memory B cells and hypogammaglobulinemia.
How is ICOSLG deficiency different from ICOS deficiency?
ICOS deficiency affects the ICOS receptor, or “lock,” on T cells, whereas ICOSLG deficiency affects the ICOSL signal, or “key,” on B cells and blood-vessel lining cells. Because ICOSL is also present on endothelial cells, ICOSLG deficiency may affect immune-cell movement through blood-vessel walls in a different way.
What causes neutropenia in ICOSLG deficiency?
People with ICOSLG deficiency can have neutropenia, and absent surface ICOSL may also make it harder for neutrophils to leave blood vessels and reach infected tissues. The exact relationship between the low neutrophil count and this cell-migration problem is not yet resolved.
Could HSCT treat ICOSLG deficiency?
HSCT has been used for some severe immune deficiencies, but published experience in ICOSLG deficiency is extremely limited. Because HSCT replaces blood-forming cells and may not correct ICOSL on blood-vessel lining cells, the potential benefits and risks require review by an expert transplant immunology team.

Get notified when new evidence is published on Late-onset combined immunodeficiency due to ICOSL deficiency.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References

References (1)
  1. 1

    Loss of human ICOSL results in combined immunodeficiency.

    Roussel L, Landekic M, Golizeh M, et al.

    The Journal of experimental medicine 2018; (215(12)):3151-3164 doi:10.1084/jem.20180668.

    PMID: 30498080

This page explains the genetics and immune effects of ICOSLG deficiency for informational purposes only and does not constitute medical advice. An immunologist, genetic counselor, and transplant specialist can interpret your results and discuss treatment decisions.